Cameron J. Turtle, MD, PhD, discuses the relationship between CD4 and CD8 T cells in patients with B-cell malignancies.
Cameron J. Turtle, MD, PhD, assistant member, Fred Hutchinson Cancer Research Center, assistant professor, University of Washington, discuses the relationship between CD4 and CD8 T cells in patients with B-cell malignancies.
Turtle says that CD4 and CD8 are two subsets of T cells that work in slightly different ways. Mouse trials have shown that CD4 and CD8 work together more effectively than on their own, particularly when used together in a chimeric antigen receptor (CAR) setting.
In the 2639 study, CD4 and CD8 T cells are taken from patients with B-cell malignancies and engineered into CAR-modified T cells before they are given back to the patient, Turtle says. In order to study the cooperation between the CD4 and CD8 T cells, each is engineered separately before they are mixed together to try to get an optimal effect on the tumor.
In the 2494 study, patients with b-cell malignancies are treated with CAR-modified T cells taken from a donor’s blood instead. Turtle says the 2949 study is done in the same fashion as the 2639 study, except that researchers have to be careful about the risk of graft-versus-host disease (GVHD). Even when modified, these T cells still possess their native receptors and the risk of alloreactivity is still present, Turtle suggests.
In order to combat this, researchers are stimulating T cells with a peptide for common viruses such as Cytomegalovirus (CMV) and Epstein-Barr (EBV) in addition to CAR to narrow down the T cell receptor range that can potentially cause GVHD.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More